Tag: acute myocardial infarction

1. Risk of acute myocardial infarction and ischemic stroke was increased during the first two weeks following a COVID-19 infection compared to the general population. 2. The risk of developing acute myocardial infarction and ischemic stroke decreased in weeks 3-4 following a COVID-19 infection compared to the first two weeks. Evidence...
1. Compared to patients only receiving rate-control treatment, those who received rhythm-control treatment within one year of diagnosis of atrial fibrillation had a lower risk of adverse cardiovascular outcomes. 2. This association was not seen if the treatment was initiated over one year after the diagnosis of atrial fibrillation. Evidence Rating...
1. Patients with an intracerebral hemorrhage (ICH) had an increased risk of ischemic stroke and myocardial infarction events compared to those without a previous ICH. Evidence Rating Level: 2 (Good) Study Rundown: Intracerebral hemorrhage (ICH) and arterial ischemic events (AIEs), such as myocardial infarction (MI) and ischemic stroke, have several risk...
1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.  Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. Biomarkers quantifying endothelial dysfunction, microvascular dysfunction, and/or hemodynamic stress provided modest diagnostic performance in the early discrimination of type 2 myocardial infarction (T2MI) from type 1 myocardial infarction (T1MI). 2. Given their limited clinical significance, clinical parameters and diagnostic investigations including coronary angiography and/or noninvasive functional or anatomic testing...
1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...
1. The PRAISE score showed accurate discriminative capabilities for the prediction of all-cause death, acute myocardial infarction, and major bleeding after an acute coronary syndrome. 2. Compared with low risk stratification, a high-risk PRAISE score was associated with a 58.8-times increase in death, 27.7-times increase in myocardial infarction, and a...
1. Although infrequently prescribed, treatment with cardiovascular medications in patients with type 2 myocardial infarction (T2MI) and acute or chronic myocardial injury may lower mortality risk. Evidence Rating Level:  2 (Good) While patients with non-ischemic myocardial injury and type 2 myocardial infarction (T2MI) are associated with poorer outcomes and higher mortality,...
1. The proportion of out of hospital cardiac arrests (OHCAs) within all acute myocardial infarction (AMI) hospital admissions was higher at the start of the COVID-19 pandemic compared to before, by a difference of 2.0%. 2. The in-hospital mortality rate for OHCAs during COVID-19 was higher than before, by a...
1. After adjustment for established cardiovascular risk factors, the diagnosis of non-alcoholic fatty liver disease (NAFLD) does not appear to be associated with risk of acute myocardial infarction or stroke.  Evidence Rating Level: 2 (Good) Recent studies indicate that non-alcoholic fatty liver disease (NAFLD) is associated with a higher risk of acute...